LIBRA
A 52-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease
- Principal investigator: Prof. Dr. Timothy Devos
- More information: NCT06975865
- Internal reference number: S70128
Vragen en contact
-
Via deze weg kunt u geen afspraak maken.